1260 results about "Peripheral blood" patented technology

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.

The invention relates to lauroyl cilostazol as well as a preparation method and application thereof. Wherein the lauroyl cilostazol is sterile, and preferably, the lauroyl cilostazol is a crystal. The invention further provides application of the lauroyl cilostazol in preparing medicines for treating cerebral infarction, cerebrovascular diseases, atherosclerosis, diabetic complications, peripheral vascular diseases, Reynolds diseases, intermittent claudication, ischemic heart diseases and acute coronary syndromes. The lauroyl cilostazol has the remarkable long-acting characteristic.

The present invention discloses a combination of different nucleic acid aptamers with 291 known targets. By performing sequencing analysis on the nucleic acid aptamer sequences of this combination through single-cell high-throughput sequencing technology, a cell atlas targeting mononuclear cells derived from the peripheral blood of patients with cholangiocarcinoma can be constructed. The nucleic acid aptamers covered by this combination have high specific affinity for their molecular targets. After extending adapters commercialized for sequencing platforms at both ends of the nucleic acid aptamer sequences respectively, by performing high-throughput sequencing on the nucleic acid aptamer sequences with sequencing adapters bound to the surface of mononuclear cells, high-throughput analysis of biomarkers on the surface of mononuclear cells derived from the peripheral blood of patients with cholangiocarcinoma can be achieved, thereby constructing a cell atlas of mononuclear cells derived from the peripheral blood of cholangiocarcinoma.

Embodiments of the invention include compositions and methods related to engineered human mucosal-associated invariant T (eMAIT) cells for off-the-shelf use for clinical therapy for cancer, infectious, and autoimmune diseases. In some embodiments, the eMAIT cells are produced from healthy human donor peripheral blood, cord blood, or G-CSF mobilized peripheral blood. In particular embodiments, the eMAIT cells are produced from a pluripotent stem cell line and therefore can be of unlimited supply. In some embodiments, the eMAIT cells are engineered to express chimeric antigen receptors (CARs), or / and immune regulatory molecules, or / and allorejection resistance molecules. Embodiments of the invention also include compositions of matter comprising polynucleotides encoding mucosal-associated invariant T cell receptor alpha chain polypeptides and / or mucosal-associated invariant T cell receptor beta chain polypeptides.

The invention discloses application of a gene marker in early screening of esophagus, stomach and intestine multiple cancer species, an early screening model construction method and a detection device, and belongs to the technical field of early noninvasive detection of digestive tract tumors. By analyzing the whole genome characteristics of circulating free DNA in peripheral blood, a novel multi-cancer-species screening system is established. On the basis of low-depth whole genome sequencing data, molecular markers in three dimensions, namely a genome copy number variation mode, a DNA fragment distribution characteristic with a specific length and an epigenetics signal of a transcription initiation region, are emphatically detected. An advanced converter neural network architecture is adopted, and the model can efficiently capture complex feature association in a whole genome range through a specific self-attention mechanism. The model design particularly considers the particularity of genome data, introduces an adaptive position coding system, and accurately reflects the spatial distribution relationship of DNA fragments on chromosomes. Therefore, the system can still maintain excellent detection performance under extremely low sequencing depth.

The invention relates to the field of noninvasive prenatal diagnosis, and particularly discloses a preeclampsia noninvasive screening method based on deep sequencing 8bp oligonucleotide double-fragment characteristics, which comprises the following steps: collecting preeclampsia and healthy pregnant woman peripheral blood samples, and extracting free DNA for high-throughput sequencing; the method comprises the following steps: extracting core 8-mer sequences' GTGCGCCC 'and' GATGGGGT 'in a long fragment of 150-200bp through bioinformatics analysis; an integrated support vector machine, K-nearest neighbor, extreme gradient lifting, a random forest and a multi-layer perceptron are combined with a logistic regression element classifier to construct a stacking model, the frequency of a core sequence is normalized, machine learning analysis is carried out, and the preeclampsia risk is predicted. According to the invention, two 8bp oligonucleotide characteristic fragments are specifically screened, and a deep learning architecture of multi-model fusion is combined, so that the limitations of low specificity and invasive detection of a traditional screening method are effectively broken through.

The invention provides a non-invasive blood pressure estimation method, device and equipment, a storage medium and a product, and belongs to the technical field of biomedicine, and the method comprises the steps that an ECG signal and an ICG signal are preprocessed; generating physiological feature indexes, wherein the physiological feature indexes comprise conventional indexes and special indexes; determining an incidence relation between the conventional index and the basic peripheral vascular resistance parameter as well as the basic artery compliance parameter; inputting the conventional indexes into a pre-trained machine learning model, and outputting basic peripheral vascular resistance prediction parameters and basic artery compliance prediction parameters; performing dynamic correction according to the special indexes, and generating a target peripheral vascular resistance parameter and a target artery compliance parameter; and calculating and generating a blood pressure estimation result. According to the non-invasive blood pressure estimation method, device and equipment, the storage medium and the product, the accuracy, dynamic nature and stability of non-invasive blood pressure estimation can be improved.

The invention discloses a reagent for rapidly distinguishing bacterial and virus infection and application, belongs to the field of molecular biology, relates to medical and biotechnology, and aims to solve the problem that a traditional method cannot clearly distinguish bacterial infection from virus infection. The reagent comprises five antibodies marked with different fluorescence. The five antibodies are all mouse anti-human or rabbit anti-human antibodies, and targets corresponding to the five antibodies are respectively CD45, CD14, CD64, CD169 and HLA-DR (human leukocyte antigen-DR). The tail end of the antibody is connected with different fluorescein through chemical reaction; fluorescence labeling is performed on neutrophils, mononuclear cells and lymphocytes in peripheral blood through an antibody combination of CD molecules, and corresponding infection indexes are calculated through a flow cytometry method, so that the infection type (bacterial / virus infection) of a patient is quickly distinguished and judged.

The invention provides an anti-human BCMA monoclonal antibody and a hybridoma cell strain, the antibody has strong affinity with a BCMA antigen, the Kd value is 1.892 * 10 <-8 > M, and the antibody can compete with a commodity BCMA antibody 19F2 to combine with a target cell; the antibody can be specifically combined with a BCMA positive cell line H929, and has no cross reaction with a BCMA negative cell line Raji and peripheral blood source T cells; the monoclonal antibody 2D2 not only can be used for detecting cells expressing human BCMA, but also can be applied to tumor immunotherapy of targeted human BCMA, and has diagnosis and treatment values.

The invention relates to the technical field of biology, in particular to a Treg cell amplification culture medium and a preparation method of Treg cells. According to the method for in-vitro amplification of the regulatory T cells (Treg) from peripheral blood, the amplification efficiency and purity of the Treg cells are improved, the culture cost is reduced, the culture period is shortened, and the problem of trophoblast cell residues in subsequent clinical application is solved.

The invention relates to the technical field of medical monitoring and intelligent decision making, and particularly discloses an intraoperative noninvasive real-time blood flow monitoring and medication intervention analysis system. Pulse wave oscillation harmonic component characteristics and diastolic attenuation characteristic characteristics are extracted by using variational mode decomposition and a polynomial fitting algorithm; the multi-dimensional features are fused and then input into a deep learning classification model, and accurate recognition of insufficient heart pump efficiency, abnormal peripheral vascular tension and circulation capacity imbalance states is achieved; time sequence prediction and grading early warning are carried out based on the hidden Markov model and the individualized baseline safety interval, and finally a targeted medication scheme is output through the intervention strategy knowledge base.

The invention provides a precise monitoring and self-adaptive regulation and control system for immunological rejection in solid organ transplantation. Relates to the field of artificial intelligence, and the system comprises a real-time data collection module which is used for collecting rejection-related biomarkers, organ function data and environment and treatment data in peripheral blood of a transplanted recipient in real time; the rejection risk prediction module is used for processing multi-dimensional time sequence characteristic data acquired in real time by adopting a long-short term memory network rejection risk prediction model based on layered boundary marginal loss function optimization, and outputting a rejection risk probability P; the intervention strategy generation module is used for generating an individualized intervention strategy through a mixed mask neighbor strategy optimization algorithm according to the current pathological state of the patient; and the intelligent decision regulation and control module is used for executing regulation and control decisions of precise regulation and control of the immunosuppressor and coordinated regulation and control of the organ microenvironment according to the rejection risk probability P and the individualized intervention strategy and performing real-time feedback. The rejection reaction recognition accuracy and intervention effectiveness are improved.

The invention belongs to the field of biological medicine industry, and discloses a blood marker for assisting in diagnosing influenza. The inventor verifies that the LRG1 is a peripheral blood marker of influenza for the first time and can be used for auxiliary diagnosis of influenza and increase of the detection rate of influenza virus by being matched with multiple times of detection of influenza virus. A test result shows that the peripheral blood LRG1 content 5ng / ml is a CUTOFF value, 46 patients and 4 false negative patients are successfully detected for 50 influenza patients, and the sensitivity is 92%; the number of normal persons is 60, the number of the normal persons is 12, and the specificity is 80%. After influenza treatment, LRG1 and Plt are obviously reduced compared with those before influenza treatment; 0.001, which is equivalent to the level of normal people, Pgt; and 0.05%.

The invention discloses a diabetes cognitive impairment method based on metabonomics analysis and prediction, and relates to the technical field of biological information, and the method comprises the following steps: S1, obtaining metabonomics data and immunomics data from a peripheral blood sample of a diabetic patient, extracting relevant time sequence data aiming at glucose metabolism, and calculating the glucose metabolism related time sequence data; processing the sequence data by adopting a time sequence analysis algorithm to obtain time sequence change characteristics; s2, constructing a cross-omics interaction network according to time sequence change characteristics, integrating an incidence relation between metabolite concentration and immune factor expression, and setting a dynamic interaction mode; according to the diabetes cognitive impairment method based on metabonomics analysis and prediction, through multi-omics data integration and dynamic network analysis, the precision and reliability of diabetes cognitive impairment mechanism analysis are remarkably improved, and a theoretical basis is provided for precise intervention.

The invention discloses a human body peripheral blood vessel photoacoustic three-dimensional imaging device and an imaging method thereof, and belongs to the field of blood vessel imaging. Through high resolution and functional monitoring capability of photoacoustic imaging, detailed blood vessel structure and blood flow dynamic information are provided, and early recognition and treatment effect evaluation of common lesions such as diabetic foot and peripheral artery diseases are promoted; meanwhile, a mechanical system is adopted, so that the detection front end with relatively high quality can be borne, and stable operation is realized, and a relatively good photoacoustic imaging result is obtained; the system has a highly stable accurate scanning imaging mode, and is convenient for multiple imaging modes of clinical application; through the arrangement of the imaging water tank and the lifting structure of the imaging water tank, switching of imaging modes in a limited space can be ensured, so that the device can be suitable for the layout of a portal type three-dimensional moving device. The system is expected to promote the portability of equipment, reduce the research and development cost of the equipment, be widely applied to clinical practice and community medical treatment, and improve the disease management level.

The invention provides an intraoperative path optimization method and system based on solid tumor preoperative image analysis, and the method comprises the steps: constructing a three-dimensional model of a tumor and peripheral blood vessels and nerves according to a preoperative image, and carrying out the dissection risk marking of the three-dimensional model through a deep learning model, generating an anatomical risk image with risk gradient value distribution; taking the minimum intraoperative bleeding amount and the highest tumor excision rate as a reward function, combining the three-dimensional model, an anatomical risk image and historical similar case data, and simulating multiple operation paths based on an adversarial reinforcement learning algorithm to obtain an optimal operation path; the method comprises the following steps: acquiring the pose, ultrasonic image and fluorescence image of a surgical instrument in real time during surgery, matching the preoperative image with the intraoperative image based on a biomechanical model driven non-rigid registration algorithm, predicting organ displacement, and correcting an optimal surgical path, thereby avoiding accidental injury of key tissues, ensuring that an infiltration area is brought into the surgical path in time, and improving the surgical efficiency. Residues are reduced, and static planning failure is avoided.

A system for remote monitoring of a workout, including: a processor; a non-transient memory; an imaging sensor; and a display device, the non-transient memory having computer-readable instructions stored thereon which, when executed by the processor, perform steps including: capturing imagery of at least a face of a subject, estimating and monitoring a peripheral blood volume pulse (BVP) or heart rate from the imagery using remote photoplethysmography (rPPG), performing facial age estimation using computer vision to analyze the imagery of the face to estimate an age of the subject, estimating a maximum heart rate using at least the age of the subject, calculating a heart rate zones as a predetermined percentage of the maximum heart rate, and displaying an indication of a current heart rate zone based on a current BVP or heart rate.

The invention relates to the technical field of biomedicine, in particular to a method for constructing a plasma ctDNA organ distribution characteristic spectrum of advanced colorectal cancer. The method comprises the following steps: collecting a peripheral blood sample at multiple time points, separating plasma by adopting a double-centrifugal method, and extracting circulating tumor DNA (Deoxyribose Nucleic Acid); carrying out whole exome sequencing based on ctDNA to obtain genome variation information and calculating variation allele frequency, and synchronously detecting the expression quantity of immune-related proteins by adopting an Olink proteomics technology; integrating the genome data, the protein expression data and the clinical pathological features, and constructing a multi-dimensional feature data matrix; and taking the organ metastasis condition confirmed by iconography as a supervision label, training a model by applying a machine learning algorithm, screening key prediction factors, constructing a quantitative prediction model, and finally generating a visual organ metastasis tendency prediction map. According to the method, early and accurate prediction of the advanced colorectal cancer organ metastasis tendency is realized through multi-omics data collaborative analysis and machine learning modeling.

The invention belongs to the field of new application of medicines, and particularly relates to application of SIRT4-IN-1 in preparation of medicines for treating autoimmune diseases. It is found for the first time that SIRT4-IN-1 reduces the activation degree of immune response induced by HSV-1 virus infection by up-regulating acetylation modification of cGAS, inhibits abnormal activation of immune response in Trex1 deficient mouse cells and peripheral blood mononuclear cells of systemic lupus erythematosus patients, and improves abnormal activation of autoimmune response. The invention provides a new candidate drug for clinical treatment of systemic lupus erythematosus.

The invention belongs to the field of biological medicine, and discloses a blood marker for identifying epilepsy convulsion and application thereof. The inventor finds that the LRG1 is obviously increased during epileptic convulsion, which indicates that the increase of the blood LRG1 is a blood marker during the acute attack stage of epileptic convulsion. The invention proposes and verifies that the LRG1 is the peripheral blood marker in the acute attack stage of epilepsy convulsion for the first time, and can be used as a clinical auxiliary diagnosis and treatment target.

The invention discloses an auxiliary diagnosis system for renal transplantation rejection and typing thereof based on a peripheral blood immune cell map. Comprising a peripheral blood single cell acquisition unit, a mass spectrum flow cytometry unit, an original data preprocessing unit, a data conversion and normalization processing unit, a peripheral blood immune cell grouping acquisition unit, a peripheral blood immune cell map construction unit, a feature vector acquisition unit, a rejection prediction unit and a rejection typing prediction unit. According to the invention, a kidney transplantation two-stage diagnosis architecture is created for the first time; rejection detection and typing identification are realized through classification of an independently trained random forest binary classifier, and different TCMR / ABMR immune mechanisms are accurately matched; the traditional biopsy limitation is broken through, an auxiliary diagnosis scheme with high precision, low damage, moderate cost and typing identification capability is provided for the kidney transplantation rejection, and the method has important significance on timely discovery of the rejection of a kidney transplantation patient and improvement of prognosis.

The invention belongs to the field of tumor medicine and the technical field of molecular biology and gene detection, and relates to application of rs17771861 in preparation of a nasopharyngeal carcinoma prognosis prediction marker, and the sequence of the SNP site rs17771861 is as shown in SEQ ID NO.1. The invention also relates to application of the SNP site rs17771861 in preparation of a nasopharyngeal carcinoma prognosis prediction marker. The invention provides an SNP (Single Nucleotide Polymorphism) marker rs17771861 related to nasopharyngeal carcinoma prognosis, application of the SNP marker rs17771861 and a detection kit capable of being used for nasopharyngeal carcinoma prognosis prediction, and the SNP marker rs17771861 is used for assisting in guiding individualized treatment and improving prognosis of tumor patients. After the kit disclosed by the invention is applied to clinical detection, prognosis of a patient can be evaluated before treatment, and a more positive and effective treatment scheme is formulated for the patient with poor prognosis, so that individualized treatment of the patient is realized, and the survival rate is increased. In addition, the kit only needs to detect peripheral blood, and has the characteristics of convenience in sampling, simplicity in operation, high timeliness and the like.

The invention relates to a construction method of a thyroid-related eye disease animal model, and belongs to the technical field of biology. The invention provides a thyroid-associated ophthalmopathy animal model construction method, which comprises: (1) separating and purifying in vitro peripheral blood collected from a thyroid-associated ophthalmopathy patient to obtain an exosome; and (2) injecting the exosome into a to-be-modeled animal to prepare the thyroid-associated ophthalmopathy animal model. According to the invention, exosomes are extracted from in-vitro peripheral blood of patients with thyroid-associated ophthalmopathy and are injected into animals, so that the thyroid-associated ophthalmopathy animal model with a plurality of pathological characteristics such as orbital tissue inflammatory response, fibrosis, orbital lesion, thyroid dysfunction and the like is successfully constructed; the method can be widely applied to pathological mechanism research of thyroid-related eye diseases and screening and evaluation of thyroid-related eye disease treatment drugs.

The invention relates to a recombinant complement protein and application thereof in preparation of anti-leukemia drugs, and belongs to the technical field of biological medicines. The invention discloses a method for treating acute leukemia by single drug, namely injecting recombinant C1QBP protein, which has a remarkable effect on treating acute leukemia, can be used for remarkably inhibiting proliferation of leukemia cells in marrow, spleen and peripheral blood of a hematopoietic system and also inhibiting infiltration of the leukemia cells in extramedullary organs (skin and the like), so that the whole-body tumor load is reduced, and the curative effect of treating acute leukemia is improved. The lifetime of leukemia mice is obviously prolonged. The recombinant C1QBP protein is combined with a clinical first-line chemotherapy regimen for use, has a synergistic effect, has a stronger effect of inhibiting leukemia cell proliferation compared with a single chemotherapy drug, can significantly prolong the lifetime of leukemia mice, and plays a role in reducing toxicity and enhancing efficacy. The invention proves that the complement C1Q binding protein has the effect of treating leukemia for the first time, provides a preparation method and a drug combination scheme, and has relatively high clinical transformation prospect and application value.

The invention belongs to the technical field of biomedicine, and particularly relates to application of GPR161 as an acute distress syndrome diagnostic marker and a therapeutic target. Experiments prove that the expression level of GPR161 in peripheral blood mononuclear cells of a patient with the acute respiratory distress syndrome is remarkably increased, and the expression quantity of the GPR161 is positively correlated with the severity of the disease, so that the GPR161 gene or GPR161 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the acute respiratory distress syndrome; a reagent for inhibiting GPR161 gene expression or protein activity can be used for preparing a medicine for treating the acute respiratory distress syndrome. The invention provides a new strategy for diagnosis, monitoring and targeted drug development of ARDS, and has important clinical application value.

The embodiment of the invention relates to the technical field of drug detection, in particular to an anti-CD38 antibody drug receptor occupation detection method and system, a peripheral blood sample is used for preparing a single-cell suspension, the single-cell suspension is divided into a TEST tube and an FMO tube, a cell surface antibody and an RO detection antibody are added into the TEST tube, only the cell surface antibody is added into the FMO tube, and only the RO detection antibody is added into the FMO tube. The TEST tube and the FMO tube are subjected to sample detection analysis, so that the average fluorescence intensity of RO detection antibodies of the TEST tube and the FMO tube is obtained. And performing RO detection analysis by adopting a dissociation method, taking the tubes which are not combined with the medicine as a total receptor group, taking the tubes which are combined with the medicine as a dissociation receptor group, and calculating an RO detection result according to the average fluorescence intensity of the TEST tube and the FMO tube.

The invention relates to a training method of a respiratory tract infection disease progress and prognosis prediction model. The training method comprises the following steps: extracting mRNA from peripheral blood of a target patient, and carrying out transcriptome sequencing to obtain a sequencing result; based on the ferroptosis related gene set, comparing ferroptosis score differences of two groups of patients with community-acquired pneumonia and sepsis, and screening corresponding ferroptosis related genes with statistical significance from a sequencing result; screening out genes meeting preset conditions from the ferroptosis related genes based on LASSO regression; and establishing an RTI clinical outcome prediction model through logistic regression by taking whether the patient is sepsis or not as an outcome dichotomy variable and taking the screened gene expression quantity as a prediction variable. According to the invention, after the prediction model is subjected to machine learning screening such as LASSO and the like, the core feature with the highest prediction value is reserved, so that the risk of over-fitting of the model on training data is reduced.

The invention discloses an ALS prognosis evaluation system based on UBE2J2 gene methylation and expression level, and relates to the technical field of biomedicine and bioinformatics. Comprising a data acquisition module, a methylation detection module, an expression quantity determination module, a data preprocessing module, a preliminary survival analysis module, a multivariable Cox proportional risk model construction module, an individualized risk index calculation and grouping module and a visualization and clinical application module. By combining UBE2J2 gene methylation and expression quantity analysis, peripheral blood non-invasive detection, standardized experiment and computational analysis process and visual presentation, the method is technically and remarkably superior to the prior art, high accuracy, operability, repeatability and expandability are realized, and the method is suitable for large-scale popularization and application. And the technical defects of single molecular marker, complicated operation, inaccurate prediction and the like in ALS prognosis evaluation in the prior art are overcome.

The invention discloses a peripheral blood and CT-based liver transplantation recipient sarcopenia classification method and device, and the method comprises the steps: carrying out the single-factor COX regression preliminary screening of collected peripheral blood biochemical indexes of liver transplantation recipients, and obtaining potential prediction factors related to sarcopenia; performing LASSO regression screening on the potential predictive factors to obtain core predictive factors related to sarcopenia; multiplying each core predictive factor by a regression coefficient calculated in LASSO regression, performing accumulation calculation to obtain an LASSO + COX model score, and dividing liver transplantation recipients into different risk groups according to the size of the LASSO + COX model score; and carrying out definite diagnosis on sarcopenia according to a risk group division result in combination with a CT image examination result. According to the method, a new strategy of peripheral blood prediction preliminary screening and high-risk CT confirmation is realized, the radiation risk, cost and detection threshold are reduced, and the sarcopenia management efficiency is improved.

The invention belongs to the field of biological medicine industry, and discloses an acute pyelonephritis peripheral blood marker. The inventor finds and verifies that the average value of LRG1 in blood is higher than that of a normal person during acute pyelonephritis for the first time, LRG1 serving as a peripheral blood marker of acute pyelonephritis has high sensitivity and specificity, and treatment of acute pyelonephritis can be guided more effectively.